A new study led by Professor Chris Parris and Dr Hussein Al-Ali at ARU demonstrated the efficacy of MDX-124, a revolutionary medicine that targets annexin-A1, a protein associated to various cancer forms.

This innovative treatment drastically lowers cancer cell proliferation and tumour growth in vivo. The ongoing clinical trial ATTAINMENT seeks to further assess MDX-124's safety and efficacy in cancer treatment.

Find out more here: https://ow.ly/yMe850QsZin
#CancerResearch #MDX124 #Immunotherapy #ARUInnovates